Table 5.
Hazard ratios for mortality according to LPV/r and DRV/r use in different subgroups.
| HR (95% CI) | ||
|---|---|---|
| Subgroups | LPV/r vs. control | DRV/r vs. control |
| Demographics | ||
| Men (N=209) | 0.45 (0.15-1.35) | 0.71 (0.50-1.01) |
| Age >50 years (N=223) |
0.54 (0.14-1.66) | 0.78 (0.28-2.09) |
| Comorbidities | ||
| Obesity | ||
| Yes (N=120) | 0.55 (0.06-5.13) | 0.89 (0.28-2.74) |
| No (N=297) | 0.35 (0.09-1.35) | 0.93 (0.28-3.07) |
| Diabetes | ||
| Yes (N=76) | 0.93 (0.16-5.16) | 2.10 (0.61-7.21) |
| No (N=341) | 0.23 (0.06-0.96) p=0.044 |
0.61 (0.20-1.84) |
| Arterial hypertension | ||
| Yes (N=164) | 1.02 (0.26-3.89) | 1.30 (0.42-4.05) |
| No (N=253) | 0.07 (0.0086-0.67) P= 0.021 |
0.56 (0.17-1.88) |
| Patient status | ||
| Degree of COVID-19 severity on chest CT scan | ||
| Grade<25% (N=265) | NA (1) | NA (2) |
| Grade>25% (N=152) |
0.35 (0.12-1.03) p=0.05 |
0.63 (0.27-1.48) |
| Impaired glucose metabolism (>110 mg/dl) | ||
| Yes (N=208) | 0.42 (0.12-1.51) | 1.28 (0.48-3.39) |
| No (N=263) | 0.18 (0.02-1.6) | NA (1) |
| Low SaO2 (<90%) | ||
| Yes (N=45) | 0.47 (0.11-1.97) | 0.58 (0.16-2.02) |
| No (N=372) | 0.29 (0.05-1.54) | 1.49 (0.45-4.91) |
| High CRP (10 mg/dl) | ||
| Yes (N=243) | 0.29 (0.07-1.14) P=0.07 |
1.15 (0.44-2.80) |
| No (N=174) | NA | NA |
| Therapies | ||
| Use of oxygen | ||
| Yes (N=137) | 0.65 (0.16-2.59) | 1.14 (0.40-3.03) |
| No (N=280) | 0.18 (0.03-1.12) p=0.05 |
0.62 (0.13-2.85) |
| Use of dexamethasone | ||
| Yes (N=228) | 0.73 (0.22-2.39) | 1.16 (0.44-3.04) |
| No (N=189) | NA | NA |
| Use of LMWH | ||
| Yes (N=330) | 0.61 (0.18-2.00) | 1.41 (0.54-3.69) |
| No (N=87) | NA | NA |
A subgroup analysis was conducted to reveal the main risk factors in mortality according to protease inhibitor use. Hazard ratios are shown with 95% CIs. Values showed NA (not applicable) meaning the inability to calculate values due to low number of patients. CRP, C-reactive protein; LMWH, Low molecular weight heparin; SaO2, arterial oxygen saturation.